8-K: Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Terns Pharmaceuticals announced its first quarter 2024 financial results, highlighting progress in its clinical programs and a cash runway into 2026.

Summary

• Terns Pharmaceuticals reported its financial results for the first quarter of 2024, ending March 31, 2024.
• The company's cash, cash equivalents, and marketable securities totaled $240.7 million as of March 31, 2024, compared to $263.4 million at the end of 2023.
• Terns anticipates that its current cash reserves will fund operations into 2026.
• Research and development expenses were $18.6 million for the quarter, up from $17.1 million in the same period last year.
• General and administrative expenses were $6.9 million, slightly down from $7.1 million in the first quarter of 2023.
• The company reported a net loss of $22.4 million for the quarter, compared to a net loss of $21.5 million in the first quarter of 2023.
• Interim data from the Phase 1 CARDINAL trial of TERN-701 for CML and top-line data from the Phase 1 trial of TERN-601 for obesity are expected in the second half of 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with progress in clinical trials and a solid cash position, but also acknowledges the inherent risks and financial losses associated with a clinical-stage biopharmaceutical company.

Positives

• The company has a strong cash position of $240.7 million, providing a runway into 2026.
• TERN-701 showed no food effect and supports once-daily dosing, a potential advantage over existing treatments.
• The FDA granted Orphan Drug Designation for TERN-701, which could provide regulatory benefits.
• Preliminary safety data for TERN-601 is positive, with no significant adverse events reported.
• The company is actively advancing multiple clinical programs and discovery efforts.

Negatives

• The company reported a net loss of $22.4 million for the first quarter of 2024.
• Cash reserves decreased from $263.4 million at the end of 2023 to $240.7 million as of March 31, 2024.

Risks

• The company's future success depends on the outcome of its clinical trials, which are subject to inherent risks and uncertainties.
• There is a risk that the clinical trial results may not be positive or may not lead to regulatory approval.
• The company's cash reserves may not be sufficient to fund operations beyond 2026 if development costs increase or if clinical trials are delayed.
• The company is subject to risks associated with the development of new drugs, including potential safety issues and regulatory hurdles.

Future Outlook

The company anticipates reporting interim data from the Phase 1 CARDINAL trial of TERN-701 in CML and top-line data from the Phase 1 trial of TERN-601 for obesity in the second half of 2024. Terns expects its current cash reserves will fund operations into 2026.

Management Comments

• Amy Burroughs, chief executive officer of Terns, stated that the company continues to execute its strategy and make important progress on its pipeline.
• Ms. Burroughs also mentioned that they are pleased with the recent findings from the Phase 1 study of TERN-701 in healthy volunteers, which showed lack of food effect and supports once-daily dosing.

Industry Context

Terns is operating in the competitive biopharmaceutical industry, focusing on developing small molecule therapies for oncology and obesity. The company's focus on oral therapies and potential combination therapies aligns with current trends in drug development. The development of a GLP-1 agonist for obesity is in line with the current high interest in this class of drugs.

Comparison to Industry Standards

• Terns' focus on oral small molecule therapies aligns with industry trends towards more convenient drug administration.
• The development of a GLP-1 agonist for obesity puts Terns in competition with companies like Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Mounjaro, Zepbound), who have established market positions in this space.
• The company's allosteric BCR-ABL inhibitor for CML is aimed at addressing limitations of existing treatments, such as the need for fasting and twice-daily dosing, potentially competing with drugs like Novartis' Tasigna.
• The company's cash runway into 2026 is a positive sign, but it will need to continue to raise capital to fund its clinical programs through to commercialization, similar to other clinical-stage biopharma companies.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and the company's cash runway.
• Employees may be impacted by the management changes and the company's overall performance.
• Customers (potential patients) may benefit from the development of new therapies for CML and obesity.
• Suppliers and creditors may be impacted by the company's financial performance and cash position.

Next Steps

• Terns plans to report interim data from the Phase 1 CARDINAL trial of TERN-701 in CML in the second half of 2024.
• The company also plans to report top-line data from the Phase 1 trial of TERN-601 for obesity in the second half of 2024.
• Terns plans to host a TERN-701-focused virtual key opinion leader (KOL) event in mid-2024.
• The company will continue to evaluate opportunities for TERN-501 in metabolic diseases.
• Terns will continue discovery efforts for small molecule GIPR modulators for obesity.

Key Dates

Keywords

Terns Pharmaceuticals, TERN-701, TERN-601, CML, obesity, GLP-1, BCR-ABL, clinical trials, financial results, biopharmaceutical, THR-beta, GIPR